NextGen Bio
Filter News
Found 6,954 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
-
The company was backed by Versant Ventures, which supported the launch of CRISPR Therapeutics.
-
Hexagon Bio, a California-based biotechnology company turning nature’s DNA into medicines for cancers and infectious diseases with unmet needs, will move into clinical research with $47 million in Series A financing.
-
Gates Foundation's Annual Goalkeepers Report Shows COVID-19 Has Stalled 20 Years of Progress, Calls for Global Response to End the Pandemic
9/15/2020
Report shows how economic damage has reinforced inequities and derailed achievement of the UN Sustainable Development Goals; spotlights countries innovating to meet challenges
-
Talaris Therapeutics Announces Collaboration With Kentucky Organ Donor Affiliates to Advance Preclinical Study of Tolerance Induction to Organs From Deceased Donors
9/14/2020
Talaris Therapeutics, Inc. , a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced a collaboration with Kentucky Organ Donor Affiliates (KODA). KODA is an independent, non-profit organ and tissue procurement organization that facilitates deceased donor transplants throughout K
-
The financing will be used by MiNA to advance the company’s pipeline of proprietary, first-in-class, small activating RNA therapeutics.
-
Anthos Therapeutics is Developing a Hemostasis-Sparing Anticoagulant to Reduce the Hazard of Blee...
9/10/2020
Earlier this year, BioSpace tallied up the hottest U.S. biotech start-ups in their NextGen Bio Class of 2020 – Anthos Therapeutics was ranked #2. -
Rockville, Maryland-based OncoImmune closed on a Series B round worth $56 million.
-
Akero Therapeutics To Present At Morgan Stanley's 18th Annual Global Healthcare Conference
9/9/2020
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Morgan Stanley's 18 th Annual Globa
-
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
-
Biospace recently analyzed key emerging cell and gene therapy companies to get a handle on how this evolving science is beginning to make its way from research into clinical applications.
-
Lumen Biosciences closed a $16 million Series B funding round that will support the development of its three clinical programs aimed at C. difficile, norovirus and traveler’s diarrhea.
-
Relation Therapeutics Teams up With Mila in Coalition to Identify COVID-19 Therapeutic Candidates
9/1/2020
Relation Therapeutics, a drug development company driven by data science and machine learning, announces Project RE, which will apply Relation Therapeutics’ and its partners’ technology to the identification of repurposed drug combinations as potential therapeutic candidates for COVID-19.
-
The idea is to support companies that anticipate “potential health security threats, activating the global innovation community, and amplifying scientific and technological advances with the aim to prepare for and respond to our rapidly evolving global health environment.”
-
New investors who joined the funding round include Viking Global Investors, Venrock Healthcare Capital Partners and Janus Henderson Investors.
-
South San Francisco-based Freenome closed on an oversubscribed $270 million Series C financing.
-
The 11-person team at Codagenix may be tiny, but it has big plans for the company’s new COVID-19 vaccine.
-
Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa
8/17/2020
Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced the beginning of a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.
-
Less than one month after GlaxoSmithKline took a 10% stake in CureVac, the Germany-based company raised $213 million in an initial public offering Thursday.